Hyperuricemia
Conditions
Interventions
Gout Intervention group:We intervened in the intervention group with dietary nutrients, which consisted mainly of concentrated or combined products of vitamins, minerals, botanicals, amino acids and e
Hyperuricemia Intervention group:We intervened in the intervention group with dietary nutrients, which consisted mainly of concentrated or combined products of vitamins, minerals, botanicals, amino ac
Gout Control group:Lifestyle changes include healthy eating, restriction of smoking and alcohol, adherence to exercise and weight control.
Hyperuricemia Control group:Lifestyle changes include healthy eating, restriction of smoking and alcohol, adherence to exercise and weight control.
Sponsors
Jiamusi University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Patients who have been diagnosed with gout and hyperuricemia (including dietary gout; obese gout); (2) Informed and voluntary participation in the study, and the informed consent form signed by the person himself; (3) Settle in the place of residence within the next 3 months; (4) Age 18-70 years old, gender is not limited;
Exclusion criteria
Exclusion criteria: (1) primary study data for outcome measures were not available; (2) Serum creatinine level >= 1.5 times the upper limit of normal or creatinine clearance 1.5 times the upper limit of normal; (3) Combined application of theophylline drugs and other urate-lowering drugs: imidazolithioprine, 6-mercaptopurine, and other salicylate drugs containing aspirin (>300mg/d), oral contraceptives or hormone replacement therapy (prednisone dosage >) within 3 months before the test 10mg/d); (4) Patients with severe cardiovascular and cerebrovascular diseases, endocrine system diseases, mental diseases, history of alcoholism, drug or other substance abuse, and cancer patients; (5) Pregnant and lactating women, as well as women of childbearing age who do not take effective contraceptive measures, or those who plan to conceive during the test, and those who have positive urine chorionic gonadotropin test results before the test; (6) Those who are participating in other clinical trials that affect the evaluation of the results of this study, or patients and their families who do not cooperate with the treatment; (7) Patients with kidney disease-type gout and exercise-type gout.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood uric acid level; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life scores;Triglycerides;Total cholesterol;BMI; | — |
Countries
China
Contacts
Public ContactYiying Zhang
Department of Epidemiology and Health Statistics, School of Public Health, Jiamusi University
Outcome results
None listed